-+ 0.00%
-+ 0.00%
-+ 0.00%

Baiyunshan (600332.SH) subsidiary's application for clinical trial of eye barrier postcards approved

Zhitongcaijing·08/10/2026 12:09:24
Listen to the news

Zhitong Finance App News, Baiyunshan (600332.SH) issued an announcement. Recently, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., a subsidiary of the company, received the approval and issuance of the “Pharmaceutical Clinical Trial Approval Notice” from the State Drug Administration on the treatment of new functions of eye disorders. Eye relief tablets have the effect of nourishing the liver and kidney and reducing freckles. It is used for dryness and discomfort, monocular diplopia, lower back and knee weakness, or mild vision loss due to liver and kidney deficiency; early and middle stage senile cataracts have the above symptoms. This drug is a traditional Chinese medicine compound preparation that has already been marketed. This time, clinical trial applications for dry eyes have been added to the application.